SE0104423D0 - Pregnane steroids and their use in the treatment of CNS disorders - Google Patents
Pregnane steroids and their use in the treatment of CNS disordersInfo
- Publication number
- SE0104423D0 SE0104423D0 SE0104423A SE0104423A SE0104423D0 SE 0104423 D0 SE0104423 D0 SE 0104423D0 SE 0104423 A SE0104423 A SE 0104423A SE 0104423 A SE0104423 A SE 0104423A SE 0104423 D0 SE0104423 D0 SE 0104423D0
- Authority
- SE
- Sweden
- Prior art keywords
- treatment
- cns disorders
- steroid
- substances
- hydroxy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, ***e
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Pregnancy & Childbirth (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (17)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0104423A SE0104423D0 (sv) | 2001-12-27 | 2001-12-27 | Pregnane steroids and their use in the treatment of CNS disorders |
PCT/SE2002/002423 WO2003059357A1 (en) | 2001-12-27 | 2002-12-20 | Pregnane steroids for use in the treatment of cns disorders |
EP02793723A EP1458399B1 (en) | 2001-12-27 | 2002-12-20 | Pregnane steroids for use in the treatment of cns disorders |
CNA2009101459540A CN101601675A (zh) | 2001-12-27 | 2002-12-20 | 用于治疗中枢神经***功能紊乱的孕烷类固醇 |
US10/499,214 US7960367B2 (en) | 2001-12-27 | 2002-12-20 | Pregnane steroids and their use in the treatment of CNS disorders |
CNA2009101459536A CN101601674A (zh) | 2001-12-27 | 2002-12-20 | 用于治疗中枢神经***功能紊乱的孕烷类固醇 |
AU2002359202A AU2002359202C1 (en) | 2001-12-27 | 2002-12-20 | Pregnane steroids for use in the treatment of CNS disorders |
EP10183670.8A EP2275109B1 (en) | 2001-12-27 | 2002-12-20 | Pregnane steroids for use in the treatment of CNS disorders |
CNB028262751A CN100518741C (zh) | 2001-12-27 | 2002-12-20 | 用于治疗中枢神经***功能紊乱的孕烷类固醇 |
DK02793723.4T DK1458399T3 (da) | 2001-12-27 | 2002-12-20 | Pregnansteroider til brug i behandlingen af CNS-sygdomme |
JP2003559519A JP2005519893A (ja) | 2001-12-27 | 2002-12-20 | Cns疾患の治療において使用するためのプレグナンステロイド |
ES02793723T ES2394639T3 (es) | 2001-12-27 | 2002-12-20 | Esteroides de pregnano para utilización en el tratamiento de trastornos del CNS |
CA2468248A CA2468248C (en) | 2001-12-27 | 2002-12-20 | Pregnane steroids for use in the treatment of cns disorders |
AU2009201951A AU2009201951A1 (en) | 2001-12-27 | 2009-05-18 | Pregnane steroids for use in the treatment of CNS disorders |
AU2009201956A AU2009201956B2 (en) | 2001-12-27 | 2009-05-18 | Pregnane steroids for use in the treatment of CNS disorders |
JP2009256620A JP5289281B2 (ja) | 2001-12-27 | 2009-11-10 | Cns疾患の治療において使用するためのプレグナンステロイド |
US12/986,937 US8119619B2 (en) | 2001-12-27 | 2011-01-07 | Pregnane steroids and their use in the treatment of CNS disorders |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0104423A SE0104423D0 (sv) | 2001-12-27 | 2001-12-27 | Pregnane steroids and their use in the treatment of CNS disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
SE0104423D0 true SE0104423D0 (sv) | 2001-12-27 |
Family
ID=20286518
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SE0104423A SE0104423D0 (sv) | 2001-12-27 | 2001-12-27 | Pregnane steroids and their use in the treatment of CNS disorders |
Country Status (10)
Country | Link |
---|---|
US (2) | US7960367B2 (xx) |
EP (2) | EP2275109B1 (xx) |
JP (2) | JP2005519893A (xx) |
CN (3) | CN101601674A (xx) |
AU (3) | AU2002359202C1 (xx) |
CA (1) | CA2468248C (xx) |
DK (1) | DK1458399T3 (xx) |
ES (1) | ES2394639T3 (xx) |
SE (1) | SE0104423D0 (xx) |
WO (1) | WO2003059357A1 (xx) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4914368B2 (ja) * | 2004-11-18 | 2012-04-11 | ウメクライン アーベー | Gaba−ステロイド拮抗剤およびcns疾患の治療のためのその使用 |
US8580983B2 (en) | 2006-11-21 | 2013-11-12 | Umecrine Ab | Steroids having increased water solubility and resistance against metabolism, and methods for their production |
US20090269795A1 (en) * | 2007-03-09 | 2009-10-29 | The Research Foundation Of State University Of New York | Mutant alpha4betadelta GABAA receptor and methods of treating anxiety or irritability |
CN101585862B (zh) * | 2008-05-20 | 2014-12-17 | 梅克芳股份公司 | 甾族化合物 |
DK2523666T3 (en) | 2010-01-14 | 2016-04-04 | Asarina Pharma Ab | A pharmaceutical composition comprising 3-beta-hydroxy-5-alpha-pregnan-20-one with improved storage and solubility properties |
RU2593751C2 (ru) | 2011-05-20 | 2016-08-10 | Энсэрм (Энститю Насьональ Де Ля Санте Э Де Ля Решерш Медикаль) | Антагонисты рецептора св1 |
SI2925770T1 (sl) | 2012-11-28 | 2017-07-31 | Institut National De La Sante Et De La Recherche Medicale(Inserm) | 3-(4'-substituirani)-benzil-eter derivati pregnenolona |
CN106163528A (zh) * | 2014-01-29 | 2016-11-23 | 梅克芳识别有限公司 | 用于治疗肝脑病的甾族化合物 |
JOP20200195A1 (ar) * | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
AR103384A1 (es) | 2015-01-12 | 2017-05-03 | Umecrine Cognition Ab | 3a-ETINILO, 3b-HIDROXI, 5a-PREGNAN-20-OXIMA COMO MODULADOR DE GABA |
US10278977B2 (en) | 2016-06-06 | 2019-05-07 | Umecrine Cognition Ab | Methods for treating hypersomnolence |
JP7278949B2 (ja) * | 2017-01-09 | 2023-05-22 | アサリナ ファーマ アーベー | 注射可能な懸濁液 |
WO2018147791A1 (en) | 2017-02-10 | 2018-08-16 | Asarina Pharma Ab | 3-beta-hydroxy-5-alpha-pregnan-20-one for use in treatment of essential tremor |
AU2018218823B2 (en) | 2017-02-10 | 2022-12-22 | Asarina Pharma Ab | 3-beta-hydroxy-5-alpha-pregnan-20-one for use in medical treatment |
RU2020130861A (ru) * | 2018-04-05 | 2022-05-05 | Асарина Фарма Апс | Антагонисты гамка для применения в лечении расстройств отмены психоактивного вещества |
WO2023083979A1 (en) * | 2021-11-10 | 2023-05-19 | Umecrine Ab | 3.beta.-hydroxy, 3.alpha.-ethyl steroids for modulation of the alpha-3 subtype of the gaba-a receptor |
CA3237550A1 (en) | 2021-11-10 | 2023-05-19 | Umecrine Ab | 3.alpha.-substituted 3.beta.-hydroxy 17-oximated androstane compound for modulation of the alpha-3 subtype of the gaba-a receptor |
WO2023083980A1 (en) | 2021-11-10 | 2023-05-19 | Umecrine Ab | Steroid as a modulator of gabaa receptor |
US11969434B1 (en) | 2022-08-29 | 2024-04-30 | Lipocine Inc. | Oral allopregnanolone compositions and methods of use |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5232917A (en) | 1987-08-25 | 1993-08-03 | University Of Southern California | Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series |
US5439900A (en) * | 1993-02-25 | 1995-08-08 | Bukusoglu; Cuneyt | Methods and compositions for providing analgesia and enhanced anesthesia |
US5939545A (en) | 1994-02-14 | 1999-08-17 | Cocensys, Inc. | Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series |
US5767117A (en) | 1994-11-18 | 1998-06-16 | The General Hospital Corporation | Method for treating vascular headaches |
CA2289096A1 (en) | 1997-05-02 | 1998-11-12 | Reinhold H. W. Bender | Pharmaceutically acceptable salts of 5alpha-pregnan-3beta, 16alpha-diol-20-one 3-sulfate useful as progestins and cns disorders |
DK0981349T3 (da) * | 1997-05-02 | 2003-03-10 | Wyeth Corp | 5-alfa-pregnan-3-beta-ol-20-on-sulfat til behandling af tumorer og CNS sygdomme |
PT980381E (pt) | 1997-05-02 | 2003-12-31 | Wyeth Corp | Sais farmaceuticamente aceitaveis de ester 3-sulfato de 5-alfa-pregn-16-en-3-beta-ol-20-ona com actividade de progesterona e uteis no tratamento de perturbacoes do snc |
JP3877961B2 (ja) * | 1998-03-11 | 2007-02-07 | ベクストルム,トルビエーン | Cns疾患の治療におけるエピアロプレグナノロン |
EP1121376A1 (en) | 1998-10-13 | 2001-08-08 | American Home Products Corporation | Pregnane glucuronides |
US20020072509A1 (en) * | 2000-10-11 | 2002-06-13 | Stein Donald Gerald | Methods for the treatment of a traumatic central nervous system injury |
-
2001
- 2001-12-27 SE SE0104423A patent/SE0104423D0/xx unknown
-
2002
- 2002-12-20 EP EP10183670.8A patent/EP2275109B1/en not_active Expired - Lifetime
- 2002-12-20 US US10/499,214 patent/US7960367B2/en not_active Expired - Fee Related
- 2002-12-20 CN CNA2009101459536A patent/CN101601674A/zh active Pending
- 2002-12-20 CN CNA2009101459540A patent/CN101601675A/zh active Pending
- 2002-12-20 CA CA2468248A patent/CA2468248C/en not_active Expired - Fee Related
- 2002-12-20 JP JP2003559519A patent/JP2005519893A/ja active Pending
- 2002-12-20 CN CNB028262751A patent/CN100518741C/zh not_active Expired - Fee Related
- 2002-12-20 DK DK02793723.4T patent/DK1458399T3/da active
- 2002-12-20 ES ES02793723T patent/ES2394639T3/es not_active Expired - Lifetime
- 2002-12-20 AU AU2002359202A patent/AU2002359202C1/en not_active Ceased
- 2002-12-20 WO PCT/SE2002/002423 patent/WO2003059357A1/en active Application Filing
- 2002-12-20 EP EP02793723A patent/EP1458399B1/en not_active Expired - Lifetime
-
2009
- 2009-05-18 AU AU2009201951A patent/AU2009201951A1/en not_active Abandoned
- 2009-05-18 AU AU2009201956A patent/AU2009201956B2/en not_active Ceased
- 2009-11-10 JP JP2009256620A patent/JP5289281B2/ja not_active Expired - Fee Related
-
2011
- 2011-01-07 US US12/986,937 patent/US8119619B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US20110098259A1 (en) | 2011-04-28 |
EP1458399B1 (en) | 2012-08-08 |
AU2009201956A1 (en) | 2009-06-11 |
JP5289281B2 (ja) | 2013-09-11 |
US20050222099A1 (en) | 2005-10-06 |
EP2275109B1 (en) | 2013-07-24 |
US8119619B2 (en) | 2012-02-21 |
EP1458399A1 (en) | 2004-09-22 |
AU2009201956B2 (en) | 2010-11-25 |
EP2275109A2 (en) | 2011-01-19 |
CA2468248C (en) | 2011-08-16 |
JP2010065052A (ja) | 2010-03-25 |
WO2003059357A1 (en) | 2003-07-24 |
AU2009201951A1 (en) | 2009-06-04 |
CN1607954A (zh) | 2005-04-20 |
AU2002359202B2 (en) | 2009-02-19 |
AU2002359202A1 (en) | 2003-07-30 |
ES2394639T3 (es) | 2013-02-04 |
AU2002359202C1 (en) | 2011-03-31 |
CA2468248A1 (en) | 2003-07-24 |
JP2005519893A (ja) | 2005-07-07 |
CN100518741C (zh) | 2009-07-29 |
CN101601675A (zh) | 2009-12-16 |
CN101601674A (zh) | 2009-12-16 |
AU2009201956A2 (en) | 2010-02-18 |
EP2275109A3 (en) | 2011-10-12 |
DK1458399T3 (da) | 2012-11-12 |
US7960367B2 (en) | 2011-06-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SE0104423D0 (sv) | Pregnane steroids and their use in the treatment of CNS disorders | |
HUS1600020I1 (hu) | Módosított VIII-as faktor | |
WO2002058684A3 (en) | Combinations of drugs (e.g., chlorpromazine and pentamidine) for the treatment of neoplastic disorders | |
AU2003272285A8 (en) | Thienopyrrolyl and furanopyrrolyl compounds and their use as histamine h4 receptor ligands | |
TW200504078A (en) | Therapeutically active compounds and their use | |
TW200509937A (en) | Novel compounds and their use in therapy | |
ID26781A (id) | Sapogenin steroid dan turunannya untuk mengobati penyakit alzheimer | |
NZ516349A (en) | Conjugates of phytosterol or phytostanol with ascorbic acid and use thereof in treating or preventing cardiovascular disease | |
WO2004006906A3 (en) | Methods for the treatment of neoplasms | |
BR0014312A (pt) | Combinação de loteprednol e anti-histaminas | |
WO2005046583A3 (en) | Modified fviii having reduced immunogenicity through mutagenesis of a2 and c2 epitopes | |
AU3703900A (en) | Nitrosated and nitrosylated steroids for the treatment of cardiovascular diseases and disorders | |
DE60322075D1 (de) | Ppar alpha selektive verbindungen zur behandlung von dyslipidämie und anderen lipidstörungen | |
BG106226A (en) | A blocking monoclinal antibody to vla-1 and its use for the treatment of inflammatory disorders | |
WO2003047507A3 (en) | Factor viii c2 domain variants | |
ATE289318T1 (de) | 17alfa, 21-dihydroxypregnene esters als antiandrogene wirkstoffe | |
DE60320034D1 (de) | Behandlung von mastitis mit einer kombination aus prednisolon und cephalosporin | |
DE602004014020D1 (de) | Prävention und behandlung von hypertonen herzerkrankungen mit den selektiven östrogenen 8beta-vinyl-estra-1,3,5(10)-trien-3,17beta-diol und 17beta-fluor-9alpha-vinyl-estra-1,3,5(10)-trien-3,16alpha-diol | |
EP1229973A4 (en) | SWING FOR THE DISABLED | |
BR0010560A (pt) | 3-piridil-4-arilpirrois substituìdos e métodos terapêuticos e profiláticos relacionados | |
NO308583B1 (no) | Anvendelse av steroider for fremstilling av et medikament for behandling av forstyrrelser indusert av østrogenmangel, steroidene samt farmasøytisk blanding | |
IL146828A0 (en) | Treatment of angiogenesis dependent conditions with dextrin sulphate | |
BR0308788A (pt) | Processos terapêuticos e usos de sapogeninas e seus derivados | |
ITBO990629A0 (it) | Dispositivo per impianto vascolare nel trattamento percutaneo delle le sioni carotidee . | |
NO20004363D0 (no) | Anvendelse av D1-/D5-antagonister for behandling av tvangsforstyrrelser, somatoforme forstyrrelser, dissosiative forstyrrelser, impulskontroll forstyrrelser og autisme |